Liquid biopsy: Illuminating cancer diagnosis with new horizons

The landscape of cancer diagnosis is undergoing a paradigm shift with the advent of liquid biopsy, a non-invasive approach that analyzes circulating biomarkers in bodily fluids. This review illuminates the transformative potential of liquid biopsy in revolutionizing cancer diagnostics, offering a comprehensive overview of its principles, technologies and clinical applications. The metaphorical “illuminating” encapsulates the hope and brightness liquid biopsy brings to the field. The paper begins by highlighting the limitations of traditional tissue biopsies, emphasizing the need for a more dynamic and less invasive methodology. The principles of liquid biopsy, centered on circulating tumour DNA (ctDNA), circulating tumour cells (CTCs) and other cancer-associated components, are explored. Various technologies, including next-generation sequencing (NGS) and digital polymerase chain reaction (dPCR), are discussed for their roles in liquid biopsy analysis. The clinical applications of liquid biopsy are examined, showcasing its efficacy in early detection, treatment selection, monitoring treatment response and detecting minimal residual disease. Challenges such as sensitivity, specificity and standardization are critically addressed and the paper concludes with a comparative analysis of liquid biopsy against traditional methods, highlighting its potential to reshape the landscape of cancer diagnostics. This review serves as a valuable resource for researchers, clinicians and policymakers navigating the forefront of cancer diagnostics.